OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting
May 18 2015 - 9:21AM
Business Wire
OPKO Health, Inc. (NYSE:OPK) today announced six important new
clinical trial results pertaining to the 4Kscore® test presented at
the 2015 American Urological Association (AUA) annual meeting, May
15 to May 19, 2015, in New Orleans.
Date and time, title and location of the
4Kscore presentations at the New Orleans Morial Convention Center
(NOMCC):
Friday, May 15, 1:00 pm – Moderated poster MP6-04: The 4Kscore
Test predicts high-grade prostate cancer on biopsy with PSA less
than 4 ng/mL; NOMCC #220-221
Sunday May 17, 11:10 am – Urologic Oncology Forum podium
presentation: Screening for lethal prostate cancer using PSA and
related blood biomarkers; NOMCC #356-357
Sunday May 17, 12:50 am – Urologic Oncology Forum podium
presentation: Use of commercial blood biomarkers to identify risk
of aggressive prostate cancer; NOMCC #356-357
Monday, May 18, 8:00 am – Moderated poster MP60-06: The
performance of the 4Kscore for predicting high-grade cancer on
biopsy of the prostate does not depend on the age of the patient;
NOMCC #206-207
Monday May 18, 10:30 am – Podium presentation PD38-03: The
4Kscore is associated with more advanced disease at radical
prostatectomy; Results from a multi-Institutional prospective
trial; NOMCC #215-216
Tuesday, May 19, 8:00 am – Moderated poster MP77-20: Among men
with low-grade prostate cancer on prostate biopsy, the 4Kscore
predicts more aggressive prostate cancer at prostatectomy; NOMCC
228-230
In addition to the regular AUA program presentations, the OPKO
4Kscore test will also be featured on Tuesday May 19th in an
industry program titled “Biomarkers and Genomic Testing in Prostate
Cancer: Integration Into Clinical Practice” from 10:00 - 11:00 am
at NOMCC Science and Technology Hall #1043
About the 4Kscore Test
The 4Kscore is the only blood test that accurately identifies
risk for aggressive prostate cancer. The 4Kscore measures the blood
levels of four different prostate-derived kallikrein proteins:
Total PSA, Free PSA, Intact PSA and Human Kallikrein-2 (hK2). These
biomarkers are combined with a patient's age, Digital Rectal Exam
(DRE) status (nodule / no nodule), and prior negative biopsy status
(yes / no) using a proprietary algorithm to calculate the risk
(probability) of finding a Gleason Score 7 or higher prostate
cancer. The four kallikrein panel of biomarkers utilized in the
4Kscore Test is based on over a decade of research conducted by
scientists at Memorial Sloan-Kettering Cancer Center and leading
European institutions. The 4Kscore Test provides individualized
risk for the presence of aggressive prostate cancer and adds new
information to the shared decision making discussion between a
Urologist and patient.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics
company that seeks to establish industry-leading positions in
large, rapidly growing markets by leveraging its discovery,
development and commercialization expertise and novel and
proprietary technologies. For more information, visit
http://www.opko.com.
SAFE HARBOR STATEMENT
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
expected benefits of the 4Kscore, whether the 4Kscore will
accurately identify men more likely to develop distant prostate
cancer metastases, whether the 4Kscore will improve long-term
prediction of distant prostate cancer metastasis, the power of the
4Kscore to provide valuable information to accurately identify
aggressive prostate cancer, including in higher risk populations,
and guide clinical decision making, whether it will accurately
predict high-grade cancers, whether it will reduce unnecessary
biopsies by at least 25%, whether OPKO will successfully
commercialize the 4Kscore, and the market for and expected sales of
4Kscore, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or
results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include
those described in our filings with the Securities and Exchange
Commission, as well as the risks inherent in funding, developing
and obtaining regulatory approvals of new, commercially-viable and
competitive products and treatments. In addition, forward-looking
statements may also be adversely affected by general market
factors, competitive product development, product availability,
federal and state regulations and legislation, the regulatory
process for new products and indications, manufacturing issues that
may arise, patent positions and litigation, among other factors.
The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150518005973/en/
OPKO Health, Inc.David Okrongly, 305-575-4133
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024